Fig. 1.

Chart shows breakdown of funding for Singaporean pulmonary arterial hypertension patients on PDE5 inhibitors. MAF: Medication Assistance Fund; MSW: medical social worker; PDE5: phosphodiesterase type 5; SHF: Singapore Heart Foundation

Chart shows breakdown of funding for Singaporean pulmonary arterial hypertension patients on PDE5 inhibitors. MAF: Medication Assistance Fund; MSW: medical social worker; PDE5: phosphodiesterase type 5; SHF: Singapore Heart Foundation